The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a huge mover today! About 101,846 shares traded hands. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has declined 25.85% since April 5, 2016 and is downtrending. It has underperformed by 27.80% the S&P500.
The move comes after 5 months positive chart setup for the $315.79 million company. It was reported on Nov, 7 by Barchart.com. We have $38.41 PT which if reached, will make NASDAQ:LJPC worth $385.26M more.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage
Out of 3 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. La Jolla Pharmaceutical Company has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was initiated on Tuesday, May 24 by Lake Street. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) earned “Outperform” rating by Cowen & Co on Tuesday, February 9. The firm earned “Buy” rating on Tuesday, September 8 by Chardan Capital Markets. The firm earned “Hold” rating on Tuesday, August 11 by Zacks.
According to Zacks Investment Research, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.9 in 2016 Q2. Its up 0.56, from 1.34 in 2016Q1. The ratio is positive, as 6 funds sold all La Jolla Pharmaceutical Company shares owned while 14 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 15.94 million shares or 0.70% less from 16.05 million shares in 2016Q1.
Analytic Ltd Co, a California-based fund reported 33,633 shares. Belmont Glob Advsr Incorporated holds 60,000 shares or 0.92% of its portfolio. Fmr Ltd Company last reported 0.01% of its portfolio in the stock. Kcg Holdings holds 13,898 shares or 0% of its portfolio. Paw Cap Corporation has 0.92% invested in the company for 50,000 shares. Susquehanna Group Limited Liability Partnership owns 13,123 shares or 0% of their US portfolio. Amer accumulated 0% or 8,013 shares. Schwab Charles Mgmt owns 21,579 shares or 0% of their US portfolio. Landscape Cap Mngmt Ltd Liability Co has invested 0.11% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Deutsche Bank Ag accumulated 0% or 33,327 shares. The New York-based Rtw Invests Ltd Liability has invested 6.43% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Moreover, Great West Life Assurance Can has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 2,654 shares. Morgan Stanley reported 138,661 shares or 0% of all its holdings. Teacher Retirement System Of Texas holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 2,042 shares. Perceptive Advisors Limited Liability Com last reported 1.33M shares in the company.
Insider Transactions: Since September 9, 2016, the stock had 1 buying transaction, and 0 insider sales for $2.76 million net activity. Another trade for 139,035 shares valued at $2.76 million was made by TANG KEVIN C on Friday, September 9.
More notable recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: Businesswire.com which released: “La Jolla Pharmaceutical Company Announces Financial Results for the Three and …” on November 03, 2016, also Businesswire.com with their article: “La Jolla Pharmaceutical Company Announces Agreement with European Medicines …” published on September 07, 2016, Businesswire.com published: “La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan …” on October 24, 2016. More interesting news about La Jolla Pharmaceutical Company (NASDAQ:LJPC) were released by: Businesswire.com and their article: “La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results …” published on May 06, 2016 as well as Businesswire.com‘s news article titled: “La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of …” with publication date: September 09, 2015.
LJPC Company Profile
La Jolla Pharmaceutical Company, incorporated on May 8, 2012, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. The Company’s product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.